ERBB2 and breast cancer: To evaluate the impact of FolTAC-dual on HER2+ and EGFR + BC, we treated various drugs on cell viability in both Trastuzumab-sensitive SKBR3-WT and Trat/Lap-resistant SKBR3 cell lines.